AVA6207 / Avacta - LARVOL DELTA

AVA6207 is a novel pre|CISION® technology compound delivering complementary TOPO1i and ATRi payloads to the tumor microenvironment following FAP cleavage (EORTC-NCI-AACR 2026) - "Abstract will be available as of 4 November (with consent of the author)"

Biomarker • Tumor microenvironment • Oncology

The in vivo data in the AVA6207 program show the dual payload delivery demonstrating prolonged deep complete responses despite tumor regrowth with the conventional cytotoxic drugs. (GlobeNewswire) - "Results indicate that deep and durable complete responses are observed in the FAP-high model, HEK-FAP where tumors regrow with conventional therapy. In the FAP-low/HER2-positive patient derived xenograft model of gastric cancer, durable responses with AVA6207 are observed where tumor regrowth is observed with Enhertu. These results suggest optimal treatment with the combination is more effective in this model than the deruxtecan-based ADC."

Preclinical • Gastric Cancer

The pre|CISION dual payload technology (AVA6207) update (Juskaite, V. et al.) (Avacta Press Release) - "The AVA6207 dual payload is designed to simultaneously release a TOP1i and a DNA Damage Repair (DDR) inhibitor by FAP cleavage, resulting in synthetic lethality in two genetic models of TOP1i resistance: tumor cells harboring either (1) ATM-deficiency or (2) loss of SLFN11....In addition to the robust exposure data, antitumor efficacy is demonstrated in a patient-derived xenograft (PDX) model of HER2+ gastric cancer with low FAP expression with optimal activity of AVA6207 over the HER2-targeted TOP1i ADC (Enhertu)."

Preclinical • Gastric Cancer